Dallas, TX, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Vivakor, Inc. (Nasdaq: VIVK) (“Vivakor” or the “Company”), an integrated provider of energy transportation, storage, reuse, and remediation service, today announced financial and operational results for the three and nine months ended September 30, 2025. Key Financial Highlights for the Three Months Ended September 30, 2025 (YoY): Revenue increased 7% to $17.0 million;Gross profit increased 173% to $4.7 million;Gross margin improved 1700 basis points to 27.8%;Ad ...

 Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor RelationsPhone: 516-997-4600 Email: jnewton@vasocorporation.com PLAINVIEW, N.Y, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional sales services and proprietary medical products, announced today that it had reached an agreement ...

Core Viewpoint - Yum Brands is exploring strategic options for Pizza Hut due to its underperformance and the need for additional actions to realize the brand's full value, which may be better executed outside of Yum [1] Group 1: Strategic Review - The company has not set a deadline for the review process, and potential outcomes may include divestiture, joint venture, or sale of a stake in Pizza Hut [2] - The review aims to address the challenges faced by Pizza Hut and improve its market position [1][2] Group 2: Historical Context - Pizza Hut has been part of Yum Brands alongside KFC and Taco Bell since PepsiCo spun off the restaurants in 1997 [3] - The announcement follows years of struggle for Pizza Hut, which has attempted to reposition itself as a delivery and carryout option [3][4] Group 3: Market Performance - Before the pandemic, Pizza Hut faced challenges in shifting its image from a dine-in venue to a delivery service [4] - Following a surge in sales during the pandemic, the chain has experienced a decline due to "pizza fatigue" as restrictions eased [4] - Pizza Hut's market share in the U.S. pizza market has decreased from 22.6% in 2019 to 18.7% in 2024, losing customers to competitors like Domino's Pizza [5] Group 4: Industry Trends - Other restaurant companies are divesting struggling parts of their businesses to improve balance sheets, indicating a trend in the industry [5][6] - Recent examples include Starbucks selling a majority stake in its China business and Jack in the Box divesting Del Taco for $115 million [6]

Core Viewpoint - Ananym Capital is urging LKQ to divest its European business, highlighting the presence of interested buyers and suggesting that the proceeds could be utilized for share buybacks [1] Group 1: Company Actions - Ananym Capital has intensified its call for LKQ to sell its European operations [1] - The potential sale is positioned as a strategic move to enhance shareholder value through share repurchases [1] Group 2: Market Interest - There are identified interested buyers for LKQ's European business, indicating a viable market for the divestiture [1]

Core Insights - Everest Group has agreed to sell the renewal rights for its Global Retail Commercial Insurance business to American International Group (AIG) for an estimated $2 billion in aggregate gross premiums written [1][2] Group 1: Transaction Details - The financial terms of the agreement have not been disclosed [1] - AIG will gain the rights to renew Everest's US, UK, European, and Asia-Pacific Commercial Retail businesses [1] - The transition of policy writing to AIG is set to begin on January 1, 2026, for regions outside the EU, with plans to include EU portfolios in the first quarter of 2026, pending regulatory approvals [2] Group 2: Strategic Implications - AIG expects the renewal rights transaction to drive incremental growth in its general insurance portfolio without requiring additional capital [3] - Everest aims to focus on its core global Reinsurance business and its Global Wholesale and Specialty Insurance businesses following the transaction [3] Group 3: Organizational Changes - Everest has introduced a new operating structure for its insurance division, emphasizing its Global Wholesale and Specialty Insurance businesses [4] - Jason Keen has been appointed CEO of Global Wholesale and Specialty Insurance to oversee these areas [4] Group 4: Leadership Statements - Everest's CEO, Jim Williamson, highlighted the opportunity to unlock long-term value for both companies and emphasized the importance of responding to evolving market needs [5] - Mark Shaw has been appointed as the chief commercial officer for Everest's International Insurance operations [5]

Core Insights - Enovis Corporation has sold its Dr. Comfort diabetic shoe business to Promus Equity Partners for up to $60 million, which includes an upfront payment of $45 million and potential future payments of up to $15 million based on performance milestones [1][2]. Group 1: Transaction Details - The sale is seen as a positive outcome for Enovis, allowing the company to sharpen its focus on core strengths in Prevention & Recovery [2]. - The divestiture is part of a strategy to streamline the portfolio, enhance profitability, and accelerate debt reduction [2]. - Enovis plans to provide further strategic commentary on the transaction during its third quarter results call on November 6 [2]. Group 2: Company and Market Position - Enovis is described as an innovation-driven medical technology growth company dedicated to developing solutions that improve patient outcomes [4]. - The company emphasizes a culture of continuous improvement and innovation, with a focus on orthopedics and related fields [4]. - Promus Equity Partners, which manages approximately $2.7 billion, aims to support Dr. Comfort's growth and enhance its service to clinicians and patients [3].

Core Insights - Owens & Minor is selling a unit that provides medical supplies and services to healthcare providers for $375 million to Platinum Equity, with the sale expected to close by the end of 2025 [8] - The decision to sell was influenced by "inbound interest" from multiple parties, prompting a broader sale process [3] - The divested unit generated net revenue of $8 billion last year, while the retained patient direct business generated $2.7 billion, indicating a strategic shift towards potentially higher-margin operations [4] Financial Performance - The patient direct business, which Owens & Minor is retaining, had an operating income of $260 million last year, compared to $53 million for the divested unit [4] - The sale allows Owens & Minor to focus on its core business of delivering medical supplies directly to patients and home health agencies [8] Strategic Moves - Owens & Minor previously attempted to strengthen its patient direct unit by acquiring Rotech Healthcare Holdings for $1.36 billion, but the deal was terminated due to a Federal Trade Commission investigation [5] - The company plans to use the proceeds from the sale to pay down debt while remaining open to smaller acquisitions [6]

Core Insights - Occidental Petroleum is positioned to enhance investments in its core oil and gas business following the divestment of its chemicals unit [1] - The company anticipates replacing the cash flow lost from the chemicals division in approximately two and a half years [1]

Core Points - Clear Channel Outdoor Holdings, Inc. has completed the sale of its Brazilian business to Publibanca Brasil S.A. for R$80 million (approximately US$15 million), marking the exit from its Latin American operations [1][2][3] - The proceeds from the sale will be used to enhance liquidity and financial flexibility, in line with the company's debt agreements, after accounting for transaction-related fees and expenses [2][3] - The CEO emphasized that this divestiture is part of a strategy to simplify and reduce risk in the business, allowing the company to focus on its U.S. operations and pay down debt [3] Financial Details - The transaction price for the Brazilian business was R$80 million, equivalent to about US$15 million [2] - The final proceeds are subject to customary post-closing adjustments and payment of transaction-related fees and expenses [2] Strategic Focus - The company aims to create shareholder value by divesting non-core assets and reinvesting in high-return opportunities within the U.S. market [3] - The divestiture aligns with the company's strategy to concentrate on its strengths in the American and Airports businesses [3][4]

Core Insights - BioCryst Pharmaceuticals has completed the sale of its European ORLADEYO business to Neopharmed Gentili for $250 million, with potential future milestones of up to $14 million [1][8] - The transaction allows BioCryst to focus on its core U.S. market, significantly improving its operating margin and cash flow generation [2][8] - Neopharmed Gentili will manage the commercialization of ORLADEYO in Europe, retaining the existing European commercial organization built by BioCryst [8] Transaction Details - The sale price of $250 million reflects a multiple of approximately 5.4 times sales over the last twelve months ending June 2025 [8] - BioCryst intends to use the proceeds to retire a $199 million Pharmakon term loan, resulting in a cleaner balance sheet for future strategic activities [8] Strategic Advantages - The divestiture of the European business, which was approximately breakeven on a direct basis, provides an immediate improvement to BioCryst's operating margin [8] - The transaction enhances BioCryst's strategic optionality and positions the company to reach the upper half of its 2025 revenue guidance range of $580 million to $600 million, even without European revenue [2][8]